Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SU-014813 in metastatic breast cancer
2005-004941-33Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SU014813 in breast cancer, sponsored by Pfizer. Primary endpoint: Overall confirmed objective response rate. Started Jan 2006; status: completed.
02
Drugs
SU014813
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004941-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004941-33.